News

BioCentury: Elicio vaccine targets oncogenic KRAS mutations

Elicio Therapeutics (Cambridge, Mass.) showed its ELI-002 vaccine generated immune responses against all common KRAS mutations, resulting in cytolytic activity against cells expressing the mutations. FULL STORY┬╗